Cardiovascular and Bone Health in Chronic Kidney Disease

Introduction to Chronic Kidney Disease

Chronic Kidney Disease (CKD) is associated with disruptions in normal bone metabolism, contributing to renal osteodystrophy, as reported by the American Journal of Kidney Diseases and the Annals of Internal Medicine 1, 2
Phosphate retention begins early in CKD (Stage 1) but serum levels typically remain normal until glomerular filtration rate (GFR) falls below 20-30 mL/min/1.73m² (CKD Stage 4), according to the American Journal of Kidney Diseases 3

The National Kidney Foundation recommends reducing dietary phosphorus intake to 100% of the DRI for age if PTH is elevated but phosphorus is still normal, and to 80% of the DRI for age if both PTH and phosphorus are elevated 1
Excessive dietary intake, particularly from processed foods with phosphate additives, increases the risk of hyperphosphatemia, with average intake being about twice the recommended dietary allowance, according to Kidney International 4
High protein diets combined with elevated PTH significantly increase hyperphosphatemia risk, as noted by Kidney International 4
Hyperphosphatemia directly decreases ionized calcium levels, stimulating PTH release, as stated by the American Journal of Kidney Diseases 3

The National Kidney Foundation recommends monitoring serum phosphorus at least every 3 months in CKD stages 3-4, and monthly monitoring for CKD stage 5 and dialysis patients 1
Treatment decisions should be based on trends of serial measurements, rather than isolated values, as recommended by the Annals of Internal Medicine 2
A comprehensive metabolic panel, including creatinine, eGFR, calcium, potassium, uric acid, and LDH, should be ordered to assess kidney function and cell lysis, as recommended by the American College of Physicians and the National Kidney Foundation 2, 3
PTH and 25-OH vitamin D levels should be measured to assess for hyperparathyroidism and vitamin D deficiency, as recommended by the Endocrine Society and the National Kidney Foundation 2, 5
Renal ultrasound and bone densitometry are used to evaluate kidney size, morphology, and possible obstructions, as well as renal osteodystrophy, as recommended by the American College of Radiology and the International Osteoporosis Foundation 6

Dietary phosphate restriction (800-1,000 mg/day) should be initiated when serum phosphorus >4.6 mg/dL in CKD Stages 3-4, or PTH levels are elevated, as recommended by the National Kidney Foundation 3, 2
Phosphate binders may be necessary when dietary restriction is insufficient, with non-calcium, non-aluminum binders like sevelamer potentially reducing vascular calcification risk, as recommended by the American Heart Association and the National Kidney Foundation 3, 7, 2
Serum phosphate, calcium, and PTH levels should be monitored every three months in patients with early CKD, as recommended by the American College of Physicians 2
Phosphate levels should be maintained between 2.7-4.6 mg/dL for CKD stages 3-4 and between 3.5-5.5 mg/dL for CKD stage 5/dialysis, as recommended by the American Journal of Kidney Diseases 3

Overlooking dietary sources of phosphorus, such as phosphorus added during food processing, which is often not labeled and has high bioavailability, can lead to inadequate management of hyperphosphatemia 3
Excessive protein restriction can lead to protein-energy wasting in dialysis patients, which is associated with increased mortality, as reported by the American Journal of Kidney Diseases 3
Focusing on isolated values rather than serial evaluations of phosphate, calcium, and PTH considered together can lead to inadequate clinical decisions 3
Ignoring chronic high phosphate intake, even in individuals with normal kidney function, can lead to sustained higher blood phosphate levels and risk for declining kidney function 3
Hyperphosphatemia is associated with increased cardiovascular morbidity and mortality, vascular and soft tissue calcification, bone mineral disorders, and progression of kidney disease, as reported by the American Journal of Kidney Diseases and Kidney International 3, 4